TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET END USER COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 67
4.2 PORTERS FIVE FORCES 68
5 INDUSTRY INSIGHTS 69
6 EPIDEMIOLOGY 70
7 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 71
7.1 REGULATORY SCENARIO IN THE U.S 71
7.2 REGULATORY SCENARIO IN AUSTRALIA 72
7.3 REGULATORY SCENARIO IN JAPAN 72
7.4 REGULATORY SCENARIO IN CHINA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 GROWING PREVALENCE OF THROAT CANCER 76
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 76
8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 77
8.2 RESTRAINTS 77
8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 77
8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 77
8.3 OPPORTUNITIES 78
8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 78
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 79
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
8.4 CHALLENGES 80
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 80
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
9 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
9.1 OVERVIEW 82
9.2 INSTRUMENTS 85
9.2.1 PATHOLOGY-BASED INSTRUMENTS 86
9.2.1.1 PCR INSTRUMENTS 86
9.2.1.2 SLIDE STAINING SYSTEMS 86
9.2.1.3 TISSUE PROCESSING SYSTEMS 87
9.2.1.4 CELL PROCESSORS 87
9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
9.2.2 IMAGING INSTRUMENTS 87
9.2.2.1 ULTRASOUND SYSTEMS 87
9.2.2.2 CT SYSTEMS 87
9.2.2.3 MRI SYSTEMS 87
9.2.2.4 OTHERS 88
9.2.3 BIOPSY INSTRUMENTS 88
9.2.4 OTHERS 88
9.3 CONSUMABLES & ACCESSORIES 88
9.3.1 KITS 89
9.3.1.1 PCR KITS 89
9.3.1.2 DNA POLYMERASE KITS 89
9.3.1.3 NUCLEIC ACID ISOLATION KITS 89
9.3.1.4 OTHERS 90
9.3.2 REAGENTS 90
9.3.2.1 ASSAYS 90
9.3.2.2 BUFFERS 90
9.3.2.3 PRIMERS 90
9.3.2.4 OTHERS 90
9.3.3 PROBES 90
9.3.4 OTHER CONSUMABLES 90
10 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
10.1 OVERVIEW 92
10.2 IMAGING TEST 95
10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
10.2.2 MRI 96
10.2.3 CHEST X-RAY 96
10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 96
10.2.5 OTHERS 96
10.3 BLOOD TEST 96
10.3.1 BLOOD CHEMISTRY TESTS 98
10.3.2 COMPLETE BLOOD COUNT (CBC) 98
10.3.3 OTHERS 98
10.4 BIOPSY 98
10.4.1 ENDOSCOPIC BIOPSY 99
10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 99
10.4.3 OTHERS 99
10.5 OTHERS 100
11 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 101
11.1 OVERVIEW 102
11.2 PHARYNGEAL CANCER 105
11.2.1 NASOPHARYNGEAL CANCER 106
11.2.2 OROPHARYNGEAL CANCER 106
11.2.3 HYPOPHARYNGEAL CANCER 106
11.3 LARYNGEAL CANCER 107
12 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 108
12.1 OVERVIEW 109
12.2 STAGE III 112
12.3 STAGE II 112
12.4 STAGE IV 113
12.5 STAGE I 114
12.6 STAGE 0 115
13 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY AGE 116
13.1 OVERVIEW 117
13.2 30-65 120
13.3 65 AND ABOVE 121
13.4 21-29 121
13.5 BELOW 21 122
14 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY END USER 123
14.1 OVERVIEW 124
14.2 HOSPITALS 127
14.3 ASSOCIATED LABS 127
14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 128
14.5 DIAGNOSTIC IMAGING CENTERS 129
14.6 CANCER RESEARCH INSTITUTES 130
14.7 OTHERS 131
15 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 132
15.1 OVERVIEW 133
15.2 DIRECT TENDER 136
15.3 RETAIL SALES 137
16 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, BY REGION 138
16.1 ASIA-PACIFIC 139
16.1.1 CHINA 150
16.1.2 JAPAN 155
16.1.3 SOUTH KOREA 160
16.1.4 INDIA 165
16.1.5 THAILAND 170
16.1.6 SINGAPORE 175
16.1.7 INDONESIA 180
16.1.8 MALAYSIA 185
16.1.9 PHILIPPINES 190
16.1.10 AUSTRALIA 195
16.1.11 VIETNAM 200
16.1.12 REST OF ASIA-PACIFIC 205
17 ASIA PACIFIC THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 206
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 206
18 SWOT ANALYSIS 207
19 COMPANY PROFILE 208
19.1 F. HOFFMANN- LA ROCHE LTD 208
19.1.1 COMPANY SNAPSHOT 208
19.1.2 REVENUE ANALYSIS 208
19.1.3 COMPANY SHARE ANALYSIS 209
19.1.4 PRODUCT PORTFOLIO 209
19.1.5 RECENT DEVELOPMENT 209
19.2 FUJIFILM CORPORATION 210
19.2.1 COMPANY SNAPSHOT 210
19.2.2 REVENUE ANALYSIS 210
19.2.3 COMPANY SHARE ANALYSIS 211
19.2.4 PRODUCT PORTFOLIO 211
19.2.5 RECENT DEVELOPMENT 211
19.3 THERMO FISHER SCIENTIFIC INC. 212
19.3.1 COMPANY SNAPSHOT 212
19.3.2 REVENUE ANALYSIS 212
19.3.3 COMPANY SHARE ANALYSIS 213
19.3.4 PRODUCT PORTFOLIO 213
19.3.5 RECENT DEVELOPMENTS 213
19.4 CANON MEDICAL SYSTEMS CORPORATION 214
19.4.1 COMPANY SNAPSHOT 214
19.4.2 REVENUE ANALYSIS 214
19.4.3 COMPANY SHARE ANALYSIS 215
19.4.4 PRODUCT PORTFOLIO 215
19.4.5 RECENT DEVELOPMENT 215
19.5 KONINKLIJKE PHILIPS N.V. 216
19.5.1 COMPANY SNAPSHOT 216
19.5.2 REVENUE ANALYSIS 216
19.5.3 COMPANY SHARE ANALYSIS 217
19.5.4 PRODUCT PORTFOLIO 217
19.5.5 RECENT DEVELOPMENT 218
19.6 ABBOTT 219
19.6.1 COMPANY SNAPSHOT 219
19.6.2 REVENUE ANALYSIS 219
19.6.3 PRODUCT PORTFOLIO 220
19.6.4 RECENT DEVELOPMENTS 220
19.7 AGILENT TECHNOLOGIES, INC. 221
19.7.1 COMPANY SNAPSHOT 221
19.7.2 REVENUE ANALYSIS 221
19.7.3 PRODUCT PORTFOLIO 222
19.7.4 RECENT DEVELOPMENT 222
19.8 BD 223
19.8.1 COMPANY SNAPSHOT 223
19.8.2 REVENUE ANALYSIS 223
19.8.3 PRODUCT PORTFOLIO 224
19.8.4 RECENT DEVELOPMENTS 224
19.9 BEIJING O&D BIOTECH CO., LTD. 225
19.9.1 COMPANY SNAPSHOT 225
19.9.2 PRODUCT PORTFOLIO 225
19.9.3 RECENT DEVELOPMENT 225
19.10 BIO-RAD LABORATORIES, INC. 226
19.10.1 COMPANY SNAPSHOT 226
19.10.2 REVENUE ANALYSIS 226
19.10.3 PRODUCT PORTFOLIO 227
19.10.4 RECENT DEVELOPMENT 227
19.11 FONAR CORP. 228
19.11.1 COMPANY SNAPSHOT 228
19.11.2 REVENUE ANALYSIS 228
19.11.3 PRODUCT PORTFOLIO 229
19.11.4 RECENT DEVELOPMENT 229
19.12 GE HEALTHCARE 230
19.12.1 COMPANY SNAPSHOT 230
19.12.2 REVENUE ANALYSIS 230
19.12.3 PRODUCT PORTFOLIO 231
19.12.4 RECENT DEVELOPMENT 231
19.13 HOLOGIC INC. 232
19.13.1 COMPANY SNAPSHOT 232
19.13.2 REVENUE ANALYSIS 232
19.13.3 PRODUCT PORTFOLIO 233
19.13.4 RECENT DEVELOPMENT 233
19.14 ILLUMINA, INC. 234
19.14.1 COMPANY SNAPSHOT 234
19.14.2 REVENUE ANALYSIS 234
19.14.3 PRODUCT PORTFOLIO 235
19.14.4 RECENT DEVELOPMENT 235
19.15 MEDONICA CO. LTD 236
19.15.1 COMPANY SNAPSHOT 236
19.15.2 PRODUCT PORTFOLIO 236
19.15.3 RECENT DEVELOPMENT 236
19.16 MERCK KGAA 237
19.16.1 COMPANY SNAPSHOT 237
19.16.2 REVENUE ANALYSIS 237
19.16.3 PRODUCT PORTFOLIO 238
19.16.4 RECENT DEVELOPMENT 238
19.17 MINFOUND MEDICAL SYSTEMS CO., LTD 239
19.17.1 COMPANY SNAPSHOT 239
19.17.2 PRODUCT PORTFOLIO 239
19.17.3 RECENT DEVELOPMENT 239
19.18 MYRIAD GENETICS, INC. 240
19.18.1 COMPANY SNAPSHOT 240
19.18.2 REVENUE ANALYSIS 240
19.18.3 PRODUCT PORTFOLIO 241
19.18.4 RECENT DEVELOPMENT 241
19.19 PLEXBIO 242
19.19.1 COMPANY SNAPSHOT 242
19.19.2 PRODUCT PORTFOLIO 242
19.19.3 RECENT DEVELOPMENT 242
19.20 QIAGEN 243
19.20.1 COMPANY SNAPSHOT 243
19.20.2 REVENUE ANALYSIS 243
19.20.3 PRODUCT PORTFOLIO 244
19.20.4 RECENT DEVELOPMENT 244
19.21 QUEST DIAGNOSTICS INCORPORATED 245
19.21.1 COMPANY SNAPSHOT 245
19.21.2 REVENUE ANALYSIS 245
19.21.3 PRODUCT PORTFOLIO 246
19.21.4 RECENT DEVELOPMENT 246
19.22 SIEMENS HEALTHCARE GMBH 247
19.22.1 COMPANY SNAPSHOT 247
19.22.2 REVENUE ANALYSIS 247
19.22.3 PRODUCT PORTFOLIO 248
19.22.4 RECENT DEVELOPMENT 248

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.